香菇多糖联合尿激酶腔内注射治疗恶性浆膜腔积液

Treatment of Malignant Serous Cavity Fluidify by Combination Intracavitary Injection of Lentinan and Urokinase

目的观察香菇多糖联合尿激酶在治疗恶性浆膜腔积液中的疗效。方法将72例恶性浆膜腔积液患者随机分组,治疗组36例,对照组36例。常规浆膜腔微创置入静脉导管引流,均在(2～3)天排净液体,腔内给药。治疗组腔内灌注香菇多糖(8～10)mg,尿激酶(10～15)万u,每周1次,连用4周为一疗程;对照组腔内灌注顺铂(60～80)mg,每周1次,连用2周,4周为一疗程,对照组治疗期间,给予水化、止吐处理。结果治疗组有效率83.3%(30/36),高于对照组的61.1%(22/36),差异有统计学意义(P<0.05);治疗组体力状态KPS评分好转率72.2%(26/36),高于对照组的36.1%(13/36),差异有统计学意义(P<0.005)。结论香菇多糖联合尿激酶腔内灌注治疗恶性浆膜腔积液疗效显著,安全性高,无明显不良反应,明显提高患者生活质量,值得临床推广应用。

Objective To investigate the efficacy of the combination injection of lentinan and urokinase for the treatment of malignant serous cavity fluidify. Methods Seventy-two patients with malignant serous cavity fluidify were randomly devided into treatment group （36 patients） and control group （36 patients）. The canal of Cuvier was inserted into the serous cavity to drain the fluidity within 2 to 3 days, and the drugs were given by intracavitary injection. Then 8 to 10 mg of lentinan and 1 10^5 to 15 10^5 U of uroki- nase were injected into the treatment group once a week for 4 weeks. While 60 to 80 mg of DDP was in- jected into the control group once a week for 2 weeks. Hydration and stopping expectoration treatment were given to the control group during the treatment peroid. Results The effective rate for the treatment group （83. 3 %, 30/36） was higher than that of the control group （61.1 %, 22/36）. Thus the effective rates between the two groups of patients showed significant difference （P〈0. 05）. The improvement rate of performance status KPS Score for the treatment group （72. 2%, 26/36） was higher than that of the control group （61.1%, 22/36）, which also showed significant difference （P〈0. 005）. Conclusion The intracavitary combination injection of Lentinan and urokinase is effictive and safe for the treatment of ma- lignant serous cavity fluidify. This method was worth to be polpularized in clinic due to the improvement of the life quality for the patients after the treatment.